Number of pages: 100 | Report Format: PDF | Published date: June 05, 2021
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
According to the deep-dive market assessment study by Growth Plus Reports, the global autoimmune disease diagnosis market was valued at US$ 4.60 million in 2022 and is expected to register a revenue CAGR of 8.70% to reach US$ 9.76 million by 2031.
Autoimmune Disease Diagnosis Market Fundamentals
Autoimmune diseases are a group of disorders where the immune system mistakenly attacks healthy cells and tissues in the body. These diseases can affect any body part, including the skin, joints, and internal organs, and can cause many symptoms. Over 80 known autoimmune diseases include rheumatoid arthritis, lupus, multiple sclerosis, and type 1 diabetes. Diagnosing autoimmune diseases can be challenging, as the symptoms are unclear and similar to those of other conditions. Diagnosing autoimmune diseases usually involves a combination of medical history, physical examination, and laboratory tests. However, even with these methods, it can take years to get a definitive diagnosis.
The autoimmune disease diagnosis market is experiencing several trends shaping the industry. One of the most significant trends is the increasing demand for personalized medicine. With the advancements in genomics and proteomics, healthcare providers can now use precision medicine to develop personalized treatments tailored to the patient's genetic makeup and disease characteristics. This trend has led to the development of advanced diagnostic tests that can identify specific biomarkers indicating autoimmune diseases.
Autoimmune disease diagnosis market companies are aggressively creating novel diagnostic methods and extending their product portfolios to meet the rising demand for autoimmune disease diagnosis. Moreover, companies are collaborating with academic institutions and other players in the industry to develop new diagnostic tools and treatments for autoimmune diseases. For instance, in 2021, Roche collaborated with the Broad Institute of MIT and Harvard to develop new diagnostic tools and therapies for autoimmune diseases.
Autoimmune Disease Diagnosis Market Dynamics
The rising prevalence of autoimmune diseases such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus is one of the major factors boosting the revenue growth of this market. According to the National Stem Cell Foundation, autoimmune diseases are the third most common cause of chronic illness in the U.S. Around 4% of the world’s population is affected by one of more than 80 different autoimmune diseases, the most common of these, including type 1 diabetes, rheumatoid arthritis, lupus, Crohn’s disease, multiple sclerosis, psoriasis, and scleroderma.
Increased R&D can potentially boost the revenue growth of the autoimmune disease diagnostics market. Research and development are critical in developing novel diagnostic techniques and therapies for autoimmune disorders, which can aid in the early and accurate diagnosis and management of these problems. As a result, organizations that spend money on R&D are more likely to produce new diagnostic instruments that can gain a greater market share, resulting in improved revenue growth. Furthermore, R&D may lead to the development of more cost-effective diagnostic tests, which can assist in boosting the rate of acceptance of these tests by healthcare providers, driving revenue growth in the autoimmune disease diagnostics market. Moreover, top players in the market are focused on developing and launching new assay kits to diagnose various types of autoimmune diseases. For instance, in September 2020, Progentec launched a novel blood test to assess the likelihood of a systemic lupus erythematosus (SLE) patient experiencing an immunologic disease flare in the ensuing 12 weeks. Therefore, such new product launches are pivotal in propelling the growth of the autoimmune disease diagnosis market.
However, the lack of skilled professionals is a factor restraining this market's revenue growth to a certain extent. Moreover, limitations of these tests, such as the variability of autoantibody results, the heterogeneity of testing, and incorrect diagnosis, are some of the other concerns.
Autoimmune Disease Diagnosis Market Ecosystem
the global autoimmune disease diagnosis market is analyzed from the following perspectives: test type, product, disease type, and region.
Autoimmune Disease Diagnosis Market by Test Type
Based on the test type, the global autoimmune disease diagnosis market is segmented into routine laboratory tests, autoantibodies & immunologic tests, inflammatory markers, and other tests.
The routine laboratory tests segment dominated the global autoimmune disease diagnostics market with a high revenue share in 2022. This dominance is attributed to the increasing demand for routine tests for early diagnosis and management of autoimmune diseases. Moreover, the availability of advanced laboratory technologies and the rising prevalence of autoimmune diseases globally are also contributing to the growth of this segment. However, the specialized tests segment is expected to grow significantly during the forecast period due to their higher accuracy and specificity in diagnosing autoimmune diseases.
Autoimmune Disease Diagnosis Market by Product
Based on the products, the global autoimmune disease diagnosis is segmented into instruments and consumables & assay kits.
In 2022, the consumables & assay kits segment accounted for most of the global autoimmune disease diagnosis revenue share. The rising prevalence of autoimmune diseases and the growing number of tests are key factors contributing to the growth of the consumables and assay kits segment. Moreover, the increasing adoption of advanced technologies such as multiplex assays and point-of-care testing is expected to further drive the growth of this segment in the coming years. The high demand for accurate and reliable diagnosis of autoimmune diseases is also anticipated to fuel the market growth.
Autoimmune Disease Diagnosis Market by Disease Type
Based on the disease type, the global autoimmune disease diagnosis is segmented into rheumatoid arthritis, systemic lupus erythematosus, scleroderma, and other diseases.
The rheumatoid arthritis segment accounted for the majority of revenue share in the global autoimmune disease diagnosis market. This can be attributed to the high prevalence of rheumatoid arthritis and the availability of advanced diagnostic tests for diagnosis. Furthermore, the increasing adoption of early diagnosis and treatment strategies for rheumatoid arthritis is expected to drive the growth of the autoimmune disease diagnosis market during the forecast period.
The lupus erythematous segment is expected to show high revenue growth in the forecast years. This growth is attributed to the increased patient pool of lupus erythematous and the rising demand for early diagnosis and treatment of autoimmune diseases. Developing advanced diagnostic technologies and increasing healthcare expenditure is also expected to drive market growth.
Autoimmune Disease Diagnosis Market by Region
Based on the region, the global autoimmune disease diagnosis market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for most of the market revenue share for the autoimmune disease diagnosis in 2022. The rising incidence of autoimmune disease in this region is one of the major factors fueling the growth of this market. According to Autoimmune Organization, There are over a hundred autoimmune disorders. One or more autoimmune disorders affect 50 million Americans. Moreover, the growing awareness of getting tested for these diseases, greater healthcare expenditure, and favorable reimbursement policies are anticipated to boost the market growth during the projected period.
The disease diagnostics market in Europe is expected to grow significantly due to the increasing prevalence of chronic diseases and the rising demand for personalized medicine. Additionally, advancements in technology and healthcare infrastructure are likely to drive the growth of this market in the region. Moreover, the European market is also expected to be driven by the increasing investments in research and development activities by key players operating in the region. Furthermore, the adoption of point-of-care and home-based diagnostic tests is anticipated to boost the market's growth further.
The Asia Pacific region is expected to grow at a higher CAGR during the forecast period. The rising prevalence of autoimmune disease and increasing awareness among the population in this region are key factors fueling the market growth. Moreover, the large population base with unmet clinical needs and the rising government spending to develop healthcare infrastructure are other factors propelling the autoimmune disease diagnosis market growth in this region.
Autoimmune Disease Diagnosis Market Competitive Landscape
The autoimmune disease diagnosis market is highly competitive due to the presence of several established players and the emergence of new companies. The key players focus on strategic collaborations, partnerships, and mergers & acquisitions to strengthen their market position and expand their product portfolio. As a result, the market is expected to experience significant growth in the coming years.
Some of the prominent companies having the largest revenue share in the global autoimmune disease diagnosis market are,
Autoimmune Disease Diagnosis Market Recent Developments
The autoimmune disease diagnosis market is expected to experience significant growth due to the increasing prevalence of autoimmune diseases and advancements in diagnostic technologies.
Asia Pacific is projected to register a high CAGR of the autoimmune disease diagnosis market during the forecast period from 2023 to 2031.
Innovation, strategic partnerships, collaborations, mergers and acquisitions, and geographical expansion are the major strategies adopted by key market players.
Based on test type, the routine laboratory tests segment dominated the market with a high revenue share.
The global autoimmune disease diagnosis market was valued at US$ 4.60 billion in 2022 and is expected to register a revenue CAGR of 8.70 % during the forecast period.
*Insights on financial performance are subject to the availability of information in the public domain